TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT06064890: A Study to Evaluate the Safety and Effect of AVB-101, a Gene Therapy Product, in Subjects With a Genetic Sub-type of Frontotemporal Dementia (FTD-GRN)

Sponsor: AviadoBio Ltd · Phase: PHASE1/PHASE2 · Area: CARDIOLOGY_METABOLIC · Target Enrollment: 20 pts

Competing Trials Overlap

12 Active Trials

Excess Burn Exposure

$1,862,520

Rescue Site Savings

+$1,241,680

Unlock Full NCT06064890 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT06064890 Rescue Dossier →